title: Prostate-specific antigen doubling time: a potential surrogate end point in hormone-refractory prostate cancer.
authors.forename: H P
authors.initials: HP
authors.lastname: Schmid
authors.forename: A
authors.initials: A
authors.lastname: Semjonow
authors.forename: R
authors.initials: R
authors.lastname: Maibach
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D008297:Male; D015337:Multicenter Studies as Topic; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D017430:Prostate-Specific Antigen; D015255:Idarubicin